Janux Therapeutics Inc (JANX) FinancialsJANXJanux Therapeutics Inc

Evaluating the bottom line, Janux Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -308.66%, while the net margin is -214.01%. These profitability ratios, combined with a Return on Equity (ROE) of -10.70%, provide a clear picture of how effectively JANX converts its operational activities into shareholder value.

In the context of the broader market, JANX competes directly with industry leaders such as TRAX and VOR. With a market capitalization of $1.11B, it holds a significant position in the sector. When comparing efficiency, JANX's gross margin of 100.00% stands against TRAX's N/A and VOR's N/A. Such benchmarking helps identify whether Janux Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Janux has reported zero revenue for several quarters, with a recent revenue of $10.27 million in Q2 2025, which was below expectations by $7.67 million. The gross margin is high at 100% for the recent quarters, but net income remains negative, indicating ongoing financial struggles.